![Benjamin Hickey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Benjamin Hickey
Präsident bei
RAYZEBIO, INC.
Vermögen: 960 641 $ am 30.06.2026
Profil
Benjamin Joseph Hickey is Director at Bristol-Myers Squibb Holdings 2002 Ltd. since 2016 and President at Rayzebio, Inc. since 2024.
Former roles include Independent Director at Surface Oncology, Inc. from 2021 to 2023, Director at Bristol-Myers Squibb Pharmaceuticals Ltd. from 2016 to 2018, Independent Director at Mural Oncology Plc from 2023 to 2025, Chief Commercial Officer & Senior Vice President at Halozyme Therapeutics, Inc. from 2018 to 2020, Chief Commercial Officer at Mirati Therapeutics, Inc. from 2020 to 2024, and Vice President-Marketing at Bristol Myers Squibb Co. from 2014 to 2016.
Education includes undergraduate and MBA degrees from St. John's University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.03.2026 | 16’672 ( 0% ) | 960 641 $ | 30.06.2026 |
Aktive Positionen von Benjamin Hickey
| Unternehmen | Position | Beginn |
|---|---|---|
| RAYZEBIO, INC. | Präsident | 26.02.2024 |
Bristol-Myers Squibb Holdings 2002 Ltd.
 Bristol-Myers Squibb Holdings 2002 Ltd. Medical DistributorsDistribution Services Operates as a holding company whose subsidiaries distributes and sells pharmaceutical products | Direktor/Vorstandsmitglied | 01.08.2016 |
Ehemalige bekannte Positionen von Benjamin Hickey
| Unternehmen | Position | Ende |
|---|---|---|
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 23.01.2024 |
| SURFACE ONCOLOGY, INC. | Direktor/Vorstandsmitglied | 08.09.2023 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2020 |
Bristol-Myers Squibb Pharmaceuticals Ltd.
 Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Direktor/Vorstandsmitglied | 03.09.2018 |
Ausbildung von Benjamin Hickey
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
57
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cancer therapies | Health Technology |
St. John's University
 St. John's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bristol-Myers Squibb Holdings 2002 Ltd.
Bristol-Myers Squibb Holdings 2002 Ltd. Medical DistributorsDistribution Services Operates as a holding company whose subsidiaries distributes and sells pharmaceutical products | Distribution Services |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage immuno-oncology company that develops cancer therapies | Health Technology |
Rayzebio, Inc.
 Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
